5/30/2023 0 Comments Sidiary 6 crackHis company, Royalty Pharma, is doubling down on its specialty investment strategy with plans to deploy $10 billion to $12 billion in capital in the next five years, up from a $7 billion forecast two years ago. But not Pablo Legorreta, who quietly pioneered a drug development niche that’s in demand. Investors have pulled back from the biotech industry in recent months. ![]() ![]() Consider Pfizer “surprised” - while a legal scholar believes that Moderna’s previous pledge about patent enforcement could be key here. In an aggressive move, it is suing Pfizer and BioNTech over their mRNA shot, alleging that their rival Covid-19 vaccine copied parts of Moderna’s vaccine technology that it had patented between 20, when it was developing an mRNA vaccine for MERS. Moderna said in March it would begin enforcing its Covid-19 vaccine patents in wealthy countries. We’ll be posting updates on our website throughout the weekend. New to Endpoints? Sign up here.Īnother round of major medical conferences is upon us, and Kyle LaHucik is in Barcelona, bringing us live coverage from the European Society of Cardiology Congress. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. ![]() Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines.
0 Comments
Leave a Reply. |